

Supplementary Information

Visible-light-promoted radical amidoarylation of arylacrylamides towards amidated oxindoles

Yu-Zhao Wang, Wu-Jie Lin, Hong-Chao Liu and Wei Yu*

*State Key Laboratory of Applied Organic Chemistry, College of Chemistry and
Chemical Engineering, Lanzhou University, Lanzhou 730000, China.*

yuwei@lzu.edu.cn


Contents

1. General information	S1
2. General procedure for the synthesis of 1	S1
3. Synthesis of <i>N</i> -pyridinium tetrafluoroborates 2	S2
4. General procedure for the synthesis of 3	S2
5. Optimization of the reaction conditions.....	S3
6. Inhibition experiment.....	S5
7. X-ray Single crystal diffraction data of 3a	S6
8. Characterization data of compounds 2	S7
9. Characterization data of compounds 3	S12
10. References.....	S25
11. Copies of NMR spectra.....	S26

General information


The NMR spectra were recorded on a Bruker AVANCE III-400 MHz or an INOVA600 MHz spectrometer in CDCl_3 , D_2O and $(\text{CD}_3)_2\text{CO}$. The chemical shifts of ^1H NMR spectra in CDCl_3 were determined with $\text{Si}(\text{CH}_3)_4$ as the internal standard ($\delta = 0.00$ ppm); the chemical shifts of ^1H NMR spectra were determined with the solvent peak as the standard in $(\text{CD}_3)_2\text{CO}$ and D_2O ($\delta = 2.05$ ppm for $(\text{CD}_3)_2\text{CO}$, $\delta = 4.79$ ppm for D_2O). The chemical shifts in ^{13}C NMR spectra were determined based on the chemical shift of CDCl_3 ($\delta = 77.0$ ppm) and $(\text{CD}_3)_2\text{CO}$ ($\delta = 29.0$ ppm). Multiplicities are given as: s (singlet), d (doublet), t (triplet), dd (doublet of doublets), q (quartet) or m (multiplet). HR-MS was performed on a Bruker APEXII FT-ICR mass instrument (ESI). Data collections for crystal structure were performed at room temperature (296 K) using $\text{MoK}\alpha$ radiation on a Bruker Smart APEXII diffractometer. Flash column chromatography was carried out on silica gel (200–300 mesh). Commercially available reagents were used without further purification. A 40 W Kessil blue LED lamp (440 nm) was used as the light source. All solvents were dried following the standard procedures before use.

2. General procedure for the synthesis of **1**^{1,2}




(1) Methacryloyl chloride (1.2 mL, 12 mmol, 1.2 equiv.) was added dropwise to a mixture of aniline (1.0 equiv.), Et_3N (2.8 mL, 2.0 mmol, 2.0 equiv.) in CH_2Cl_2 (2.0 mL) at 0°C . After stirring at 0°C for 30 min and room temperature overnight, the mixture was quenched with saturated NaHCO_3 solution. The mixture was extracted with CH_2Cl_2 (3×25 mL), washed with brine, and dried over Na_2SO_4 . After filtration and concentration, the crude amide was used in next step without further purification.

(2) NaH (0.8 g, 60% in mineral oil, 20 mmol, 2.0 equiv.) was added to a solution of the above crude amide in THF (50 mL) at 0°C in portions. After stirring for 20 min at 0°C , MeI (1.9 mL, 3.0 mmol, 3.0 equiv.) was added dropwise and the mixture was stirred overnight. The resulting mixture was quenched with water, extracted with ethyl acetate (2×30 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 , and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel using petroleum ether (PE)/ethyl acetate (EA) to give the pure products **1a–1p**, **1t–1u**.




Methacryloyl chloride (1.2 mL, 12 mmol, 1.2 equiv.) was added to a mixture of tetrahydroquinoline (1.25 mL, 10 mmol, 1.0 equiv.), Et₃N (2.8 mL, 2.0 mmol, 2.0 equiv.) in CH₂Cl₂ (2.0 mL) at 0 °C dropwise. After stirring at 0 °C for 30 min and room temperature overnight, the mixture was quenched with saturated NaHCO₃ solution. The mixture was extracted with CH₂Cl₂ (3×25 mL), and the combined organic phases were washed with brine, and dried over Na₂SO₄. After filtration and concentration, the crude material was purified by column chromatography on silica gel using PE/EA to give the pure product **1q**. Compounds **1q–1s** and **1v** were prepared in the same way.

3. Synthesis of *N*-pyridinium tetrafluoroborates **2**³



To a solution of pyrylium salt (1.0 equiv.) in ethanol was added hydrazine (1.0 equiv.) at room temperature. The reaction mixture was stirred at room temperature for 12 h. The mixture was cooled to 0 °C and petroleum ether was added. The precipitate was collected, washed with Et₂O and dried to give products **2**.

4. General procedure for the preparation of **3**



1 (0.3 mmol, 1.5 equiv.), **2** (0.2 mmol, 1.0 equiv.), K₃PO₄ (0.24 mmol, 1.2 equiv.) and *fac*-Ir(ppy)₃ (2.0 mol%, 0.02 equiv.) were added into an 15 mL oven-dried glass tube, and the tube was evacuated and backfilled with argon (repeated three times). Dichloroethane (DCE) (2.0 mL) was added to the tube and the reaction mixture was irradiated with a 40 W Kessil blue LED lamp (50% intensity) at ambient temperature for 36 h. After completion of the reaction (monitored by TLC), the solvent was removed under vacuum. The residue was purified by column chromatography on silica gel (eluting with PE /EA) to afford products **3**.

Gram-scale preparation

1a (1.05 g, 6.0 mmol, 1.5 equiv.), **2a** (1.3 g, 4.0 mmol, 1.0 equiv.), K₃PO₄ (1.02 g,

4.8 mmol, 1.2 equiv.) and *fac*-Ir(ppy)₃ (52 mg, 2.0 mol%, 0.02 equiv.) were added into an 100 mL oven-dried glass tube, the tube was evacuated and backfilled with argon (repeated three times). DCE (30 mL) was then added to the tube and the reaction mixture was irradiated with a 40 W Kessil blue LED lamp (100% intensity) for 42 h. After completion of the reaction (monitored by TLC), the solvent was removed under vacuum. The residual was purified by column chromatography on silica gel (eluting with PE /EA) to afford 0.71 g of **3a** (61% yield).





Figure S1. Experiment setup

5. Optimization of the reaction conditions

Table S1. Screening of the photocatalyst


Entry	Photocatalyst	Yield (%) ^a
1	<i>fac</i> -Ir(ppy) ₃	65
2	Ir(dtbpv)(ppy) ₂ PF ₆	23
3	Ru(bpy) ₃ Cl ₂	N.R.
4	Cu(dap) ₂ Cl	N.R.
5	Ru(phen) ₃ Cl ₂	trace ^b
6	Eosin Y	trace ^b
7	4-CzIPN	trace ^b

Reaction conditions: **1a** (0.1 mmol, 1.0 equiv.), **2a** (0.12 mmol, 1.2 equiv.), photocatalyst (2.0 mol%), DCM (dichloromethane) (1.0 mL), 40 W blue LED (50 % intensity), ambient temperature, 24 h, under argon atmosphere. ^aIsolated yields. ^bMost of S.M. was recovered.

Table S2. Screening of the solvent

Entry	Solvent	Yield (%) ^a
1	DCM	65
2	MeCN	58
3	DCE	68
4	CHCl ₃	54
5	THF	N.R.
6	HFIP	N.R.
7	DMF	trace ^d
8	DMSO	41
9	toluene	32
10	MeOH	10
11	Acetone	58

Reaction conditions: **1a** (0.1 mmol, 1.0 equiv.), **2a** (0.12 mmol, 1.2 equiv.), *fac*-Ir(ppy)₃ (2.0 mol%), solvent (1.0 mL), 40 W blue LEDs (50 % intensity), room temperature, 24 h, under argon atmosphere. ^aIsolated yields. ^bMost of S.M. was recovered. HFIP = hexafluoroisopropanol.

Table S3. Screening of the additive

Entry	Photocatalyst	Solvent	Additive (equiv.)	Yield (%) ^a
1	<i>fac</i> -Ir(ppy) ₃	DCM	InCl ₃ (0.2)	54
2	<i>fac</i> -Ir(ppy) ₃	DCM	FeCl ₃ (0.2)	56
3	<i>fac</i> -Ir(ppy) ₃	DCM	K ₃ PO ₄ (1.0)	61
4	<i>fac</i> -Ir(ppy) ₃	DCE	K ₃ PO ₄ (1.0)	73
5	<i>fac</i> -Ir(ppy) ₃	CHCl ₃	K ₃ PO ₄ (1.0)	65
6	<i>fac</i> -Ir(ppy) ₃	DMSO	K ₃ PO ₄ (1.0)	20
7	Ir(dtbpv)(ppy) ₂ PF ₆	DCM	K ₃ PO ₄ (1.0)	71
8	Ir(dtbpv)(ppy) ₂ PF ₆	MeCN	NaOAc (1.0)	65
9	Ir(dtbpv)(ppy) ₂ PF ₆	DCM	NaOAc (1.0)	68

Reaction conditions: **1a** (0.1 mmol, 1.0 equiv.), **2a** (0.12 mmol, 1.2 equiv.), *fac*-Ir(ppy)₃ (2.0 mol%), solvent (1.0 mL), 40 W blue LED (50 % intensity), room temperature, 24 h, under argon atmosphere. ^aIsolated yields.

Table S4. Effect of the ratio of **1a** with **2a**

Entry	1a	2a	Solvent	Yield of 3a (%) ^b
1	1.0	1.5	MeCN	69
2	1.0	1.5	DCM	70
3	1.0	1.5	DCE	73
4	1.0	1.5	CHCl ₃	61
5	1.5	1.0	MeCN	56
6	1.5	1.0	DCM	74
7	1.5	1.0	DCE	81
8	1.5	1.0	CHCl ₃	64
9	1.5	1.0	DCE	58 ^c
10	1.5	1.0	DCE	74 ^d

Reaction conditions: **1a** (0.1 mmol, 1.0 equiv.), **2a** (0.12 mmol, 1.2 equiv.), *fac*-Ir(ppy)₃ (2.0 mol%), solvent (1.0 mL), K₃PO₄ (1.2 equiv.), 40 W blue LED (50 % intensity), room temperature, 36 h, under argon atmosphere. ^bIsolated yields. ^cReaction time 12 h, ^dReaction time 24 h.


Table S5. Screening of the base

Entry	1a	2a	Base	Yield of 3a (%) ^a
1	1.5	1.0	Na ₃ PO ₄	61
2	1.5	1.0	K ₂ CO ₃	64
3	1.5	1.0	NaOAc	60
4	1.5	1.0	Et ₃ N	41
5	1.5	1.0	no	61
6	1.5	1.0	K ₃ PO ₄	N.R. ^b
7	1.5	1.0	K ₃ PO ₄	N.R. ^c
8	1.5	1.0	DBU	48
9	1.5	1.0	DABCO	23

Reaction conditions: **1a** (0.1 mmol, 1.0 equiv.), **2a** (0.12 mmol, 1.2 equiv.), *fac*-Ir(ppy)₃ (2.0 mol%), solvent (1.0 mL), base (1.2 equiv.), 40 W blue LED (50 % intensity), room temperature, 36 h, under argon atmosphere. ^aIsolated yields. ^bIn the dark, ^cNo photocatalyst.

6. Inhibition experiment


TEMPO trapping experiment.




1a (0.3 mmol, 1.5 equiv.), **2a** (0.2 mmol, 1.0 equiv.), K₃PO₄ (0.24 mmol, 1.2 equiv.), 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (2.0 equiv.) and *fac*-Ir(ppy)₃ (2.0 mol%, 0.02 equiv.) were added sequentially into an oven-dried glass tube, the tube was evacuated and backfilled with argon (repeated three times). DCE (2.0 mL) was then added to the tube and the reaction mixture was irradiated with a 40 W kessil

blue LED lamp (50% intensity) for 36 h. TLC analysis indicates that no reaction took place and **3a** was not generated. **1a** and TEMPO were recovered mostly.


BHT trapping experiment.



1a (0.3 mmol, 1.5 equiv.), **2a** (0.2 mmol, 1.0 equiv.), K_3PO_4 (0.24 mmol, 1.2 equiv.), 2,6-di-tert-butyl-4-methylphenol (BHT) (2.0 equiv.) and *fac*- $\text{Ir}(\text{ppy})_3$ (2.0 mol%, 0.02 equiv.) were added sequentially into an oven-dried glass tube, the tube was evacuated and backfilled with argon (repeated three times). DCE (2.0 mL) was then added to the tube and the reaction mixture was irradiated with a 40 W kessil blue LED (50% intensity) lamp for 36 h. After completion of the reaction (monitored by TLC), the solvent was removed under vacuum. The crude product was purified by flash chromatography on silica gel directly to give the desired product **3a** with 10% yield. The BHT trapping product **4** was detected by HRMS. HRMS (EI) for **4**: m/z [$\text{M} + \text{H}$]⁺ calcd for $\text{C}_{22}\text{H}_{29}\text{NO}_2$: 340.2271; Found: 340.2272.



7. X-ray Single crystal diffraction data of 3a



Bond precision: C-C = 0.0026 Å Wavelength= 1.54184

Cell: a=9.1402(4) b=9.4815(4) c=18.9795(6)
 alpha=96.936(3) beta=91.503(3) gamma=101.596(3)

Temperature: 303 K

	Calculated	Reported
Volume	1597.30(11)	1597.29(11)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C ₁₈ H ₁₈ N ₂ O ₂	C ₁₈ H ₁₈ N ₂ O ₂
Sum formula	C ₁₈ H ₁₈ N ₂ O ₂	C ₁₈ H ₁₈ N ₂ O ₂
Mr	294.34	294.34
Dx, g cm ⁻³	1.224	1.224
Z	4	4
Mu (mm ⁻¹)	0.647	0.647
F000	624.0	624.0
F000'	625.84	
h,k,lmax	11, 11, 23	11, 11, 23
Nref	6707	6407
Tmin,Tmax	0.890,0.950	0.691,1.000
Tmin'	0.862	

Correction method= # Reported T Limits: Tmin=0.691 Tmax=1.000
 AbsCorr = MULTI-SCAN

Data completeness= 0.955

Theta(max)= 76.545


R(reflections)= 0.0433(4837)

wR2(reflections)= 0.1308(6407)


S = 1.060

Npar= 402


8. Characterization data of compounds 2




1-Benzamido-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2a): yellow solid; m.p. = 98–100 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 11.25 (s, 1H), 8.09 (d, $J = 7.7$ Hz, 2H), 7.68 (t, $J = 7.4$ Hz, 1H), 7.56–7.55 (m, 4H), 2.69 (s, 6H), 2.60 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 164.2, 160.6, 157.7, 134.1, 129.3, 128.5, 128.0, 127.7, 22.0, 19.3; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}^+$: 241.1335; Found, 241.1340.



2,4,6-Trimethyl-1-(4-methylbenzamido)pyridin-1-ium tetrafluoroborate (2b): white solid; m.p. = 136–138 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 11.21 (s, 1H), 7.99 (d, $J = 8.3$ Hz, 2H), 7.56 (s, 2H), 7.37 (d, $J = 8.0$ Hz, 2H), 2.70 (s, 6H), 2.61 (s, 3H), 2.46 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 164.2, 160.3, 157.9, 145.2, 129.9, 128.0, 127.6, 125.7, 22.0, 21.7, 19.4; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}^+$: 255.1492; Found, 255.1494.




1-(4-Methoxybenzamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2c): white solid; m.p. = 126–128 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 11.16 (s, 1H), 8.09–8.05 (m, 2H), 7.54 (s, 2H), 7.06–7.03 (m, 2H), 3.90 (s, 3H), 2.70 (s, 6H), 2.61 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 164.3, 163.8, 160.2, 158.0, 130.2, 127.6, 120.6, 114.5, 55.6, 22.1, 19.4; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}_2^+$: 271.1441; Found, 271.1443.



1-(4-Chlorobenzamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2d): white solid; m.p. = 154–156 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 11.22 (s, 1H), 7.98 (d, $J = 8.3$ Hz, 2H), 7.56 (s, 1H), 7.37 (d, $J = 8.0$ Hz, 2H), 2.70 (s, 6H), 2.61 (s, 3H), 2.46 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 163.3, 160.7, 157.6, 140.7, 129.6, 129.5, 127.8, 126.9, 22.0, 19.3; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{15}\text{H}_{16}\text{ClN}_2\text{O}^+$: 275.0946; Found,


275.0946.



2e

1-(3-Chlorobenzamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2e):


white solid; m.p. = 142–144 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 11.40 (s, 1H), 8.06 (t, J = 1.8 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.67–7.65 (m, 2H), 7.57–7.52 (m, 3H), 2.71 (s, 6H), 2.63 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 163.1, 160.7, 157.7, 135.6, 134.2, 130.8, 130.2, 128.6, 127.7, 125.6, 22.1, 19.4; HRMS-ESI (m/z) [M] $^+$ calcd for $\text{C}_{15}\text{H}_{16}\text{ClN}_2\text{O}^+$: 275.0946; Found, 275.0948.



2f

1-(2-Chlorobenzamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2f):


white solid; m.p. = 138–140 °C; ^1H NMR (CDCl_3 , 600 MHz) δ : 11.07 (s, 1H), 7.76 (d, J = 5.0 Hz, 1H), 7.59 (s, 2H), 7.53 (d, J = 2.6 Hz, 2H), 7.47–7.43 (m, 1H), 2.78 (s, 6H), 2.60 (s, 3H); ^{13}C NMR (CDCl_3 , 150 MHz) δ : 163.8, 160.9, 157.8, 133.5, 132.1, 131.1, 129.8, 129.6, 127.8, 127.6, 22.1, 19.6; HRMS-ESI (m/z) [M] $^+$ calcd for $\text{C}_{15}\text{H}_{16}\text{ClN}_2\text{O}^+$: 275.0946; Found, 275.0950.



2g

1-(4-Bromobenzamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2g):

white solid; m.p. = 140–142 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 11.37 (s, 1H), 7.99–7.96 (m, 2H), 7.74–7.70 (m, 2H), 7.57 (s, 2H), 2.70 (s, 6H), 2.63 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 163.5, 160.6, 157.7, 132.6, 129.6, 129.5, 127.7, 127.3, 22.1, 19.4; HRMS-ESI (m/z) [M] $^+$ calcd for $\text{C}_{15}\text{H}_{16}\text{BrN}_2\text{O}^+$: 319.0441; Found, 319.0444.




2h

2,4,6-Trimethyl-1-(4-(trifluoromethyl)benzamido)pyridin-1-ium


tetrafluoroborate (2h): white solid; m.p. = 198–200 °C; ^1H NMR ($(\text{CD}_3)_2\text{CO}$, 400 MHz) δ : 8.33 (d, J = 8.1 Hz, 2H), 8.03 (s, 1H), 8.01 (s, 3H), 2.82 (s, 6H), 2.72 (s, 3H); ^{13}C NMR ($(\text{CD}_3)_2\text{CO}$, 100 MHz) δ : 163.5, 161.8, 157.4, 134.2 (q, J = 32 Hz, 1C),

133.4, 129.1, 128.2, 126.1 (q, $J = 5.0$ Hz, 1C), 123.8 (q, $J = 270$ Hz, 1C), 21.2, 18.5; HRMS-ESI (m/z) $[M]^+$ calcd for $C_{16}H_{16}F_3N_2O^+$: 309.1209; Found, 309.1210.




2i

2,4,6-Trimethyl-1-(nicotinamido)pyridin-1-ium tetrafluoroborate (2i): white solid; m.p. = 146–148 °C; 1H NMR (D_2O , 400 MHz) δ : 9.27 (t, $J = 0.92$ Hz, 1H), 9.06–9.03 (m, 1H), 8.89 (d, $J = 5.8$ Hz, 1H), 8.16–8.13 (m, 1H), 7.55 (s, 2H), 2.50 (s, 6H), 2.48 (s, 3H); ^{13}C NMR (D_2O , 100 MHz) δ : 165.5, 154.9, 152.4, 145.0, 143.1, 141.3, 134.9, 127.2, 127.0, 20.4, 18.2; HRMS-ESI (m/z) $[M]^+$ calcd for $C_{14}H_{16}N_3O^+$: 242.1288; Found, 242.1291.




2j

1-(Isonicotinamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2j): white solid; m.p. = 142–144 °C; 1H NMR (D_2O , 400 MHz) δ : 8.77 (d, $J = 6.4$ Hz, 2H), 8.36 (d, $J = 6.8$ Hz, 2H), 7.43 (s, 2H), 2.38 (s, 6H), 2.36 (s, 3H); ^{13}C NMR (D_2O , 100 MHz) δ : 166.6, 154.8, 152.6, 152.0, 142.0, 127.0, 125.5, 20.4, 18.1; HRMS-ESI (m/z) $[M]^+$ calcd for $C_{14}H_{16}N_3O^+$: 242.1288; Found, 242.1285.




2k

1-(Furan-2-carboxamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2j): white solid; m.p. = 122–124 °C; 1H NMR ($CDCl_3$, 400 MHz) δ : 11.25 (s, 1H), 7.73 (s, 1H), 7.56 (s, 2H), 7.48 (d, $J = 3.5$ Hz, 1H), 2.72 (s, 6H), 2.62 (s, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 160.7, 158.1, 155.2, 147.5, 143.1, 127.3, 118.8, 112.7, 22.2, 19.5; HRMS-ESI (m/z) $[M]^+$ calcd for $C_{13}H_{15}N_2O_2^+$: 231.1128; Found, 231.1130.




2l

2,4,6-Trimethyl-1-(2-phenylacetamido)pyridin-1-ium tetrafluoroborate (2l) : white solid; m.p. = 102–104 °C; 1H NMR ($(CD_3)_2CO$, 400 MHz) δ : 7.87 (s, 2H), 7.48 (d, $J = 7.2$ Hz, 2H), 7.41–7.37 (m, 2H), 7.34–7.31 (m, 1H), 3.98 (s, 2H), 3.04 (s, 1H), 2.63 (s, 3H), 2.61 (s, 6H); ^{13}C NMR ($(CD_3)_2CO$, 100 MHz) δ : 168.5, 161.3, 157.2, 133.7, 129.5, 128.7, 127.9, 127.4, 40.1, 20.1, 18.3; HRMS-ESI (m/z) $[M]^+$ calcd for $C_{16}H_{19}N_2O^+$: 255.1492; Found, 255.1488.




2m

1-Acetamido-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2m): white solid; m.p. = 103–105 °C; ^1H NMR ($(\text{CD}_3)_2\text{CO}$, 400 MHz) δ : 7.91 (s, 2H), 2.72 (s, 6H), 2.65 (s, 3H), 2.32 (s, 3H); ^{13}C NMR ($(\text{CD}_3)_2\text{CO}$, 100 MHz) δ : 167.7, 161.2, 157.2, 127.9, 21.0, 19.6, 18.4; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}^+$: 179.1179; Found, 179.1182.




2n

1-(Cyclopropanecarboxamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2n): white solid; m.p. = 99–101 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 10.74, (s, 1H), 7.58 (s, 2H), 2.64 (s, 6H), 2.58 (s, 3H), 1.97-1.94 (m, 1H), 1.10–1.06 (m, 4H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 171.9, 160.8, 157.4, 127.8, 21.9, 19.2, 12.3, 9.0; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{12}\text{H}_{17}\text{N}_2\text{O}^+$: 205.1335; Found, 205.1339.




2o

1-(Cyclohexanecarboxamido)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2n): white solid; m.p. = 122–124 °C; ^1H NMR ($(\text{CD}_3)_2\text{CO}$, 400 MHz) δ : 7.91 (s, 2H), 3.07 (s, 1H), 2.75–2.68 (m, 7H), 2.65 (s, 3H), 2.02 (m, 1H), 1.84–1.80 (m, 2H), 1.73–1.68 (m, 1H), 1.57 (dq, $J = 3.0, 12.2$ Hz, 2H), 1.40 (td, $J = 3.2, 12.4$ Hz, 2H), 1.29 (tt, $J = 2.8, 12.0$ Hz, 1H) 1.14–1.09 (m, 1H); ^{13}C NMR ($(\text{CD}_3)_2\text{CO}$, 100 MHz) δ : 173.1, 161.1, 157.1, 127.9, 42.4, 25.4, 25.1, 21.1, 18.4; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{15}\text{H}_{23}\text{N}_2\text{O}^+$: 247.1805; Found, 247.1807.



2p


1-Isobutyramido-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2p): white solid; m.p. = 108–110 °C; ^1H NMR ($(\text{CD}_3)_2\text{CO}$, 400 MHz) δ : 7.92 (s, 2H), 2.69 (s, 6H), 2.64 (s, 3H), 1.30 (s, 3H), 1.29 (s, 3H); ^{13}C NMR ($(\text{CD}_3)_2\text{CO}$, 100 MHz) δ : 174.2, 161.2, 157.1, 128.0, 33.0, 21.1, 18.4; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{12}\text{H}_{19}\text{N}_2\text{O}^+$: 207.1492; Found, 207.1489.



2q


1-((Tert-butoxycarbonyl)amino)-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (2q): white solid; m.p. = 92–94 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 9.54 (s, 1H), 7.61 (s, 2H), 2.67, (s, 6H), 2.57 (s, 3H), 1.53 (s, 9H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 160.9, 158.0, 152.0, 127.8, 84.7, 27.9, 22.0, 19.1; HRMS-ESI (m/z) $[\text{M}]^+$ calcd for $\text{C}_{13}\text{H}_{21}\text{N}_2\text{O}_2^+$: 237.1598; Found, 237.1599.

9. Characterization data of compounds 3




3a

N-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3a): The resultant residue was purified by flash silica gel column chromatography to afford **3a** as colorless solid (46 mg, 78%); m.p. = 112–114 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.82–7.80 (m, 2H), 7.52–7.48 (m, 1H), 7.45–7.38 (m, 3H), 7.34–7.30 (m, 2H), 7.12 (m, 1H), 6.89 (m, 1H), 4.24 (dd, $J = 8.4, 13.6$, 1H), 3.27–3.23 (m, 4H), 1.47 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.3, 167.5, 142.8, 134.3, 132.0, 131.5, 128.6, 128.5, 127.0, 123.2, 123.1, 108.4, 47.2, 45.1, 26.3, 20.2; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2$: 295.1441; Found, 295.1445.




3b


N-((1,3,6-Trimethyl-2-oxoindolin-3-yl)methyl)benzamide (3b): The resultant residue was purified by flash silica gel column chromatography to afford **3b** as white solid (39 mg, 68%); m.p. = 81–83 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.84–7.82 (m, 2H), 7.52–7.39 (m, 4H), 7.14–7.10 (m, 2H), 6.78 (d, $J = 7.8$ Hz, 1H), 4.26 (dd, $J = 8.6, 13.6$ Hz, 1H), 3.23 (s, 3H), 3.18 (dd, $J = 2.5, 13.6$ Hz, 1H), 2.36 (s, 3H), 1.46 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.2, 167.4, 140.3, 134.3, 132.8, 132.1, 131.4, 128.7, 128.5, 126.9, 123.8, 108.1, 47.0, 45.1, 26.2, 21.1, 20.2; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_2$: 309.1598; Found, 309.1601.



***N*-((1,3,4-Trimethyl-2-oxoindolin-3-yl)methyl)benzamide or *N*-((1,3,6-Trimethyl-2-oxoindolin-3-yl)methyl)benzamide (3c):** The resultant residue was purified by flash silica gel column chromatography to afford **3c** as yellow solid (37 mg, 61%); m.p. = 116–118 °C; ¹H NMR (CDCl₃, 400 MHz) δ: 7.83–7.77 (m, 3.3H), 7.52–7.38 (m, 7H), 7.23–7.18 (m, 1.7H), 6.94–6.88 (m, 1.6H), 6.73 (d, *J* = 7.6 Hz, 1.6H), 4.48 (dd, *J* = 8.2, 13.6 Hz, 1H), 4.23 (dd, *J* = 8.2, 13.6 Hz, 0.6H), 3.33 (dd, *J* = 3.0, 13.6 Hz, 1H), 3.24–3.19 (m, 5.5H), 2.50 (s, 3H), 2.40 (s, 1.8H), 1.55 (s, 3H), 1.45 (s, 1.8H); ¹³C NMR (CDCl₃, 100 MHz) δ: 180.5, 180.2, 167.4, 143.1, 142.8, 138.7, 135.0, 134.2, 131.4, 129.0, 128.8, 128.5, 128.3, 126.9, 126.9, 125.8, 123.6, 122.7, 109.3, 106.1, 48.0, 46.9, 45.1, 26.3, 26.1, 21.7, 20.2, 18.4, 18.1; HRMS-ESI (m/z) [M + H]⁺ calcd for C₁₉H₂₀N₂O₂: 309.1598; Found, 309.1601.




***N*-((1,3,7-Trimethyl-2-oxoindolin-3-yl)methyl)benzamide (3d):** The resultant residue was purified by flash silica gel column chromatography to afford **3d** as yellow oil (17 mg, 28%); ¹H NMR (CDCl₃, 400 MHz) δ: 7.86–7.83 (m, 2H), 7.53–7.43 (m, 4H), 7.15 (dd, *J* = 1.3, 6.9 Hz, 1H), 7.06–6.99 (m, 2H), 4.24 (dd, *J* = 8.6, 13.6 Hz, 1H), 3.53 (s, 3H), 3.15 (dd, *J* = 2.5, 13.6 Hz, 1H), 2.60 (s, 3H), 1.44 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ: 181.1, 167.5, 140.5, 134.3, 132.7, 132.3, 131.5, 128.6, 127.0, 123.1, 120.9, 120.1, 46.3, 45.3, 29.6, 20.6, 19.0; HRMS-ESI (m/z) [M + H]⁺ calcd for C₁₉H₂₀N₂O₂: 309.1598; Found, 309.1600.




***N*-((6-(*tert*-Butyl)-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3e):** The resultant residue was purified by flash silica gel column chromatography to afford **3e** as yellow oil (43 mg, 62%); ¹H NMR (CDCl₃, 400 MHz) δ: 7.87–7.85 (m, 2H),

7.53–7.43 (m, 4H), 7.36–7.34 (m, 2H), 6.83 (dd, $J = 0.8, 8.0$ Hz, 1H), 4.31 (dd, $J = 8.7, 13.6$ Hz, 1H), 3.24 (s, 3H), 3.16 (dd, $J = 2.3, 13.6$ Hz, 1H), 1.48, (s, 3H), 1.33 (s, 9H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.6, 167.6, 146.6, 140.4, 134.4, 131.8, 131.5, 128.6, 127.0, 125.1, 120.2, 107.9, 47.2, 45.2, 34.7, 31.6, 26.3, 20.3; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}_2$: 351.2067; Found, 351.2069.




3f

***N*-((5-Methoxy-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3f)** : The resultant residue was purified by flash silica gel column chromatography to afford **3f** as yellow oil (38 mg, 59%); ^1H NMR (CDCl_3 , 600 MHz) δ : 7.84–7.82 (m, 2H), 7.50 (t, $J = 7.3$ Hz, 1H), 7.45–7.40 (m, 3H), 6.94 (d, $J = 2.4$ Hz, 1H), 6.85–6.83 (m, 1H), 6.81–6.79 (m, 1H), 4.26 (dd, $J = 8.6, 13.6$ Hz, 1H), 3.81 (s, 3H), 3.23 (s, 3H), 3.20 (dd, $J = 2.4, 13.6$ Hz, 1H), 1.46 (s, 3H); ^{13}C NMR (CDCl_3 , 150 MHz) δ : 180.0, 167.5, 156.5, 136.2, 134.3, 133.4, 131.5, 128.6, 127.0, 113.1, 110.2, 108.9, 55.9, 47.5, 45.1, 26.3, 20.3; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_3$: 325.1547; Found, 325.1550.




3g


***N*-((5-Fluoro-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3g)**: The resultant residue was purified by flash silica gel column chromatography to afford **3g** as white solid (45 mg, 72%); m.p. = 118–120 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.80–7.78 (m, 2H), 7.51–7.47 (m, 1H), 7.45–7.41 (m, 2H), 7.28 (d, $J = 6.0$ Hz, 1H), 7.08 (dd, $J = 2.5, 7.8$ Hz, 1H), 7.01 (dt, $J = 2.6, 8.6$ Hz, 1H), 6.80 (q, $J = 4.2$ Hz, 1H), 4.19 (dd, $J = 8.2, 13.6$ Hz, 1H), 3.29 (dd, $J = 3.2, 13.6$ Hz, 1H), 3.24 (s, 3H); ^{19}F NMR (CDCl_3 , 376 MHz) δ : 119.3; ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.8, 167.4, 159.5 (d, $J = 240$ Hz, 1C), 138.7 (d, $J = 1.8$ Hz, 1C), 134.1, 133.6 (d, $J = 8.0$ Hz, 1C), 131.5, 128.5, 126.9, 114.7 (d, $J = 23.4$ Hz, 1C), 111.4, (d, $J = 24.7$ Hz, 1C), 108.8 (d, $J = 8.1$ Hz, 1C), 47.8 (d, $J = 1.4$ Hz, 1C), 44.9, 26.3, 20.1; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{FN}_2\text{O}_2$: 313.1347; Found, 313.1349.



***N*-((5-Chloro-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3h):** The resultant residue was purified by flash silica gel column chromatography to afford **3h** as colorless oil (44 mg, 67%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.80, (d, $J = 7.2$ Hz, 2H), 7.50 (t, $J = 7.6$ Hz, 1H), 7.44 (t, $J = 7.6$ Hz, 2H), 7.31–7.24 (m, 3H), 6.81 (d, $J = 8.0$ Hz, 1H), 4.22 (dd, $J = 8.4, 13.6$ Hz, 1H), 3.27–3.23 (m, 4H), 1.46 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.7, 167.5, 141.4, 134.1, 133.6, 131.6, 128.6, 128.5, 126.9, 123.7, 109.3, 47.6, 44.9, 26.3, 20.1; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{ClN}_2\text{O}_2$: 329.1051; Found, 329.1054.




***N*-((4-Chloro-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide or *N*-((6-Chloro-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3i):** The resultant residue was purified by flash silica gel column chromatography to afford **3i** as yellow solid (36 mg, 55%); m.p. = 113–115 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.80–7.76 (m, 3H), 7.53–7.41 (m, 4.5H), 7.28–7.21 (m, 3H), 7.11–7.05 (m, 1.5H), 6.89 (dd, $J = 1.8$ Hz, 0.5H), 6.79 (dd, $J = 0.8, 7.8$ Hz, 1H), 4.65 (dd, $J = 8.3, 13.6$ Hz, 1H), 4.19 (dd, $J = 8.2, 13.6$ Hz, 0.5H), 3.41 (dd, $J = 3.0, 13.6$ Hz, 1H), 3.29 (dd, $J = 3.3, 13.6$ Hz, 0.5H), 3.25 (s, 3H), 3.24 (s, 1.5H), 1.62 (s, 3H), 1.45 (s, 1.5H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.2, 180.0, 167.5, 167.4, 144.7, 144.1, 134.4, 134.3, 134.2, 131.6, 131.5, 131.2, 131.0, 129.8, 128.6, 128.6, 128.1, 127.0, 124.3, 124.1, 123.0, 109.2, 106.9, 48.9, 47.3, 44.9, 42.7, 26.5, 26.4, 20.3, 17.6; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{ClN}_2\text{O}_2$: 329.1051; Found, 329.1054.




***N*-((5-Bromo-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3j):** The resultant residue was purified by flash silica gel column chromatography to afford **3j** as brown solid (43 mg, 58%); m.p. = 120–122 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.82–7.80 (m,


2H), 7.53–7.49 (m, 1H), 7.46–7.43 (m, 4H), 7.27 (d, $J = 10.3$ Hz, 1H), 6.78 (d, $J = 6.4$ Hz, 1H), 4.24 (dd, $J = 8.4, 13.6$ Hz, 1H), 3.25–3.21 (m, 4H), 1.47 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.6, 167.5, 141.8, 134.1, 134.0, 131.5, 131.4, 128.5, 126.9, 126.4, 115.8, 109.8, 47.5, 44.9, 26.3, 20.1; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{BrN}_2\text{O}_2$: 373.0546; Found, 373.0550.



***N*-((4-Bromo-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide** or
***N*-((6-Bromo-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3k):** The resultant residue was purified by flash silica gel column chromatography to afford **3k** as yellow oil (42 mg, 57%); ^1H NMR (CDCl_3 , 600 MHz) δ : 7.79–7.75 (m, 2.7H), 7.50–7.47 (m, 1.4H), 7.42 (q, $J = 8.8$ Hz, 2.7H), 7.26–7.16 (m, 4H), 7.03 (d, $J = 1.6$ Hz, 0.3H), 6.82 (dd, $J = 0.6, 7.6$ Hz, 1H), 4.70 (dd, $J = 8.4, 13.6$ Hz, 1H), 4.17 (dd, $J = 8.2, 13.6$ Hz, 0.3H), 3.42 (dd, $J = 3.0, 13.6$ Hz, 1H), 3.31 (dd, $J = 3.0, 13.6$ Hz, 0.3H), 3.23 (s, 3H), 3.22 (s, 1H), 1.63 (s, 3H), 1.45 (s, 1H); ^{13}C NMR (CDCl_3 , 150 MHz) δ : 180.0, 179.6, 167.5, 167.3, 145.0, 144.2, 134.3, 134.2, 131.6, 131.5, 130.9, 130.0, 129.8, 128.6, 128.6, 127.4, 127.0, 127.0, 125.9, 124.5, 122.1, 119.2, 111.9, 107.4, 49.6, 47.4, 44.8, 42.5, 26.5, 26.4, 20.2, 17.5; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{BrN}_2\text{O}_2$: 373.0546; Found, 373.0549.




***N*-((5-acetyl-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3l):** The resultant residue was purified by flash silica gel column chromatography to afford **3l** as yellow oil (48 mg, 71%); ^1H NMR (CDCl_3 , 600 MHz) δ : 8.00 (dd, $J = 1.7, 8.2$ Hz, 1H), 7.95 (d, $J = 1.6$ Hz, 1H), 7.79–7.77 (m, 2H), 7.51–7.48 (m, 1H), 7.44–7.42 (m, 2H), 7.19 (d, $J = 5.6$ Hz, 1H), 6.95 (d, $J = 8.2$ Hz, 1H), 4.27 (dd, $J = 8.4, 13.6$ Hz, 1H), 3.32 (dd, $J = 3.2, 13.6$ Hz, 1H), 3.29 (s, 3H), 2.60 (s, 3H), 1.51 (s, 3H); ^{13}C NMR (CDCl_3 , 150 MHz) δ : 196.7, 180.5, 167.6, 147.1, 134.2, 132.6, 132.2, 131.6, 130.3, 128.6, 127.0, 123.3, 108.0, 47.4, 45.0, 26.6, 26.5, 20.2; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_3$: 337.1547; Found, 337.1551.




***N*-((1,3-Dimethyl-2-oxo-5-(trifluoromethoxy)indolin-3-yl)methyl)benzamide**

(3m): The resultant residue was purified by flash silica gel column chromatography to afford **3m** as yellow solid (50 mg, 66%); m.p. = 105–107 °C; ¹H NMR (CDCl₃, 400 MHz) δ: 7.80–7.78 (m, 2H), 7.52–7.48 (m, 1H), 7.45–7.41 (m, 2H), 7.28–7.23 (m, 2H), 7.21–7.18 (m, 1H), 6.87 (d, *J* = 8.4 Hz, 1H), 4.21 (dd, *J* = 8.3, 13.6 Hz, 1H), 3.31 (dd, *J* = 3.2, 13.6 Hz, 1H), 3.25 (s, 3H), 1.48 (s, 3H); ¹⁹F NMR (CDCl₃, 376 MHz) δ: 58.3; ¹³C NMR (CDCl₃, 100 MHz) δ: 179.9, 167.5, 145.0 (q, *J* = 1.6 Hz, 1C), 141.4, 134.1, 133.5, 131.6, 128.6, 126.9, 121.6, 120.5 (q, *J* = 255 Hz, 1C), 117.2, 108.8, 47.8, 44.8, 26.4, 20.1; HRMS-ESI (*m/z*) [*M* + *H*]⁺ calcd for C₁₉H₁₇F₃N₂O₃: 379.1264; Found, 379.1266.



***N*-((5-Cyano-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3n):**


The resultant residue was purified by flash silica gel column chromatography to afford **3n** as white solid (50 mg, 79%); m.p. = 108–110 °C; ¹H NMR (CDCl₃, 400 MHz) δ: 7.75 (d, *J* = 7.2 Hz, 2H), 7.64 (d, *J* = 8.1 Hz, 1H), 7.60 (s, 1H), 7.51 (t, *J* = 7.2 Hz, 1H), 7.43 (t, *J* = 7.6 Hz, 2H), 7.08 (d, *J* = 4.0 Hz, 1H), 6.95 (d, *J* = 8.2 Hz, 1H), 4.16 (dd, *J* = 8.0, 13.6 Hz, 1H), 3.42 (dd, *J* = 4.0, 13.6 Hz, 1H), 3.28 (s, 3H), 1.49 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ: 179.8, 167.5, 146.7, 133.9, 133.8, 133.0, 131.7, 128.6, 126.9, 126.6, 118.8, 108.8, 106.2, 47.7, 44.7, 26.5, 20.1; HRMS-ESI (*m/z*) [*M* + *H*]⁺ calcd for C₁₉H₁₇N₃O₂: 320.1394; Found, 320.1395.



ethyl-3-(Benzamidomethyl)-1,3-dimethyl-2-oxoindoline-5-carboxylate (3o):


The resultant residue was purified by flash silica gel column chromatography to afford **3o** as white solid (53 mg, 72%); m.p. = 164–166 °C; ¹H NMR (CDCl₃, 400 MHz) δ: 8.09 (dd, *J* = 1.6, 8.2 Hz, 1H), 8.01 (d, *J* = 1.2 Hz, 1H), 7.82–7.80 (m, 2H), 7.53–7.49 (m, 1H), 7.46–7.42 (m, 2H), 7.28–7.25 (m, 1H), 6.94 (d, *J* = 8.2 Hz, 1H), 4.41–4.28 (m, 3H), 3.28 (s, 3H), 3.24 (dd, *J* = 2.8, 13.6 Hz, 1H), 1.51 (s, 3H), 1.42 (t, *J* = 7.2 Hz,

3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.4, 167.4, 166.0, 146.7, 134.1, 131.8, 131.5, 131.2, 128.5, 126.9, 125.3, 124.2, 107.9, 60.9, 47.1, 44.8, 26.4, 19.9, 14.3; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_4$: 367.1652; Found, 367.1656.




***N*-((1,3-Dimethyl-2-oxo-5-(trifluoromethyl)indolin-3-yl)methyl)benzamide (3p):**

The resultant residue was purified by flash silica gel column chromatography to afford **3p** as colorless solid (40 mg, 56%); m.p. = 126–128 °C; ^1H NMR (CDCl_3 , 600 MHz) δ : 7.80–7.79 (m, 2H), 7.61–7.58 (m, 2H), 7.52–7.49 (m, 1H), 7.45–7.42 (m, 2H), 7.21 (d, J = 6.2 Hz, 1H), 6.96, (d, J = 8.2 Hz, 1H), 4.25 (dd, J = 8.4, 13.6 Hz, 1H), 3.30–2.74 (m, 4H), 1.50 (s, 3H); ^{19}F NMR (CDCl_3 , 376 MHz) δ : 61.5; ^{13}C NMR (CDCl_3 , 150 MHz) δ : 180.1, 167.5, 145.8, 134.2, 132.6, 131.6, 128.6, 127.2, 126.9, 126.3 (q, J = 4.4 Hz, 1C), 125.4, (q, J = 32 Hz, 1C), 124.2 (q, J = 270 Hz, 1C), 120.2 (q, J = 3.4 Hz, 1C), 108.2, 47.4, 44.8, 26.4, 20.0; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_2$: 363.1315; Found, 363.1317.




***N*-((1-Methyl-2-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)methyl)benzamide (3q):**

The resultant residue was purified by flash silica gel column chromatography to afford **3q** as yellow oil (35 mg, 55%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.83–7.81 (m, 2H), 7.51–7.39 (m, 4H), 7.14 (d, J = 7.2 Hz, 1H), 7.07 (d, J = 7.0 Hz, 1H), 7.00 (t, J = 7.4 Hz, 1H), 7.25 (dd, J = 8.4, 13.6 Hz, 1H), 3.74 (t, J = 5.8 Hz, 2H), 3.25 (dd, J = 2.7, 13.6 Hz, 1H), 2.81 (t, J = 6.0 Hz, 2H), 2.04 (p, J = 6.2 Hz, 2H), 1.48 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.1, 167.4, 138.5, 134.3, 131.4, 130.6, 128.5, 127.3, 126.9, 122.6, 120.8, 120.5, 48.4, 45.1, 38.8, 24.4, 21.1, 20.0; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_2$: 321.1598; Found, 321.1602.




***N*-((1-Benzyl-3-methyl-2-oxoindolin-3-yl)methyl)benzamide (3r):** The resultant residue was purified by flash silica gel column chromatography to afford **3r** as


colorless oil (37 mg, 50%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.73–7.71 (m, 2H), 7.54–7.47 (m, 2H), 7.38 (t, $J = 7.2$ Hz, 2H), 7.26 (s, 5H), 7.20 (dt, $J = 1.1, 7.7$ Hz, 2H), 7.11–7.07 (m, 1H), 6.79 (d, $J = 7.7$ Hz, 1H), 4.94 (q, $J = 20.0$ Hz, 2H), 4.27 (dd, $J = 7.8, 13.6$ Hz, 1H), 3.46 (dd, $J = 3.2, 13.6$ Hz, 1H), 1.52 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.4, 167.5, 142.0, 135.6, 134.2, 131.9, 131.5, 128.9, 128.6, 128.5, 127.8, 127.2, 127.0, 123.2, 123.2, 109.4, 47.6, 45.2, 43.7, 20.6; HRMS-ESI (m/z) [$M + H$] $^+$ calcd for $\text{C}_{24}\text{H}_{22}\text{N}_2\text{O}_2$: 371.1754; Found, 371.1757.



***N*-((3-Methyl-2-oxo-1-phenylindolin-3-yl)methyl)benzamide (3s):** The resultant residue was purified by flash silica gel column chromatography to afford **3s** as yellow oil (41 mg, 58%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.83 (d, $J = 7.2$ Hz, 2H), 7.55, (t, $J = 7.8$ Hz, 2H), 7.49–7.40 (m, 8H), 7.28–7.24 (m, 1H), 7.17 (t, $J = 7.2$ Hz, 1H), 6.88 (d, $J = 7.6$ Hz, 1H), 4.37 (dd, $J = 8.6, 13.6$ Hz, 1H), 3.39 (dd, $J = 2.8, 13.6$ Hz, 1H), 1.60 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.9, 167.5, 142.7, 134.2, 134.0, 131.8, 131.5, 129.7, 128.5, 128.4, 128.3, 127.0, 126.4, 123.6, 123.4, 109.7, 47.5, 45.3, 20.5; HRMS-ESI (m/z) [$M + H$] $^+$ calcd for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}_2$: 357.1598; Found, 357.1601.




***N*-((4,6-Dichloro-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3t):** The resultant residue was purified by flash silica gel column chromatography to afford **3t** as colorless oil (30 mg, 42%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.74–7.72 (m, 2H), 7.51–7.48 (m, 1H), 7.42 (t, $J = 7.7$ Hz, 1H), 7.17 (d, $J = 4.6$ Hz, 1H), 7.07 (d, $J = 1.6$ Hz, 1H), 6.79 (d, $J = 1.6$ Hz, 1H), 4.53 (dd, $J = 8.0, 13.6$ Hz, 1H), 3.50 (dd, $J = 3.5, 13.6$ Hz, 1H), 3.22 (s, 3H), 1.59 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.6, 167.8, 145.5, 135.2, 131.8, 131.7, 128.6, 127.0, 126.5, 123.8, 107.9, 49.0, 42.8, 26.7, 17.6; HRMS-ESI (m/z) [$M + H$] $^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{Cl}_2\text{N}_2\text{O}_2$: 363.0662; Found, 363.0664.




***N*-((4,6-Dimethoxy-1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3u):** The resultant residue was purified by flash silica gel column chromatography to afford **3u**


as yellow oil (32 mg, 45%); ^1H NMR (CDCl_3 , 600 MHz) δ : 7.81 (d, $J = 5.0$ Hz, 2H), 7.49 (t, $J = 4.8$ Hz, 1H), 7.43 (t, $J = 5.2$ Hz, 3H), 6.21 (d, $J = 1.1$ Hz, 1H), 6.13 (d, $J = 1.1$ Hz, 1H), 4.30 (dd, $J = 5.0, 13.6$ Hz, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.36 (dd, $J = 2.0, 13.6$ Hz, 1H), 3.21 (s, 3H), 1.50 (s, 3H); ^{13}C NMR (CDCl_3 , 150 MHz) δ : 180.9, 167.4, 161.9, 157.0, 144.9, 134.7, 131.3, 128.5, 127.0, 109.8, 92.6, 88.7, 55.7, 55.5, 47.2, 44.2, 26.4, 18.3; HRMS-ESI (m/z) [$M + H$] $^+$ calcd for $\text{C}_{20}\text{H}_{22}\text{N}_2\text{O}_4$: 355.1652; Found, 355.1656.



***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)-4-methylbenzamide (3ab):** The resultant residue was purified by flash silica gel column chromatography to afford **3ab** as colorless solid (43 mg, 70%); m.p. = 122–124 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.71 (d, $J = 8.1$ Hz, 2H), 7.34–7.29 (m, 3H), 7.23 (d, $J = 8.0$ Hz, 2H), 7.15–7.11 (m, 1H), 6.89 (d, $J = 7.7$ Hz, 1H), 4.24 (dd, $J = 8.4, 13.6$ Hz, 1H), 3.25–3.21 (m, 4H), 2.39 (s, 3H), 1.46 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.3, 167.4, 142.7, 141.9, 132.0, 131.4, 129.2, 128.5, 126.9, 123.1, 123.0, 128.3, 47.2, 45.0, 26.2, 21.4, 20.1; HRMS-ESI (m/z) [$M + H$] $^+$ calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_2$: 309.1598; Found, 309.1599.




***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)-4-methoxybenzamide (3ac):** The resultant residue was purified by flash silica gel column chromatography to afford **3ac** as colorless oil (40 mg, 62%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.80–7.77 (m, 2H), 7.34–7.30 (m, 2H), 7.25 (d, $J = 10.6$ Hz, 1H), 7.14–7.10 (m, 1H), 6.94–6.88 (m, 3H), 4.24 (dd, $J = 8.4, 13.6$ Hz, 1H), 3.84 (s, 3H), 3.25 (s, 3H), 3.22 (dd, $J = 2.8, 13.6$ Hz, 1H), 1.46 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.3, 167.0, 162.1, 142.8, 132.1, 128.7, 128.4, 126.6, 123.1, 123.0, 113.7, 108.3, 55.3, 47.2, 45.0, 26.2, 20.1; HRMS-ESI (m/z) [$M + H$] $^+$ calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_3$: 325.1547; Found, 325.1548.




4-Chloro-*N*-((1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3ad): The resultant residue was purified by flash silica gel column chromatography to afford


3ad as yellow oil (34 mg, 52%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.76 (d, $J = 8.5$ Hz, 2H), 7.41 (d, $J = 8.2$ Hz, 3H), 7.33 (t, $J = 7.7$ Hz, 2H), 7.13 (t, $J = 7.6$ Hz, 1H), 6.90 (d, $J = 7.7$ Hz, 1H), 4.24 (dd, $J = 8.5, 13.6$ Hz, 1H), 3.26 (s, 3H), 3.21 (dd, $J = 2.6, 13.6$ Hz, 1H), 1.46 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.3, 166.4, 142.8, 137.8, 132.7, 132.0, 128.9, 128.6, 128.5, 123.3, 123.0, 108.5, 47.1, 45.2, 26.3, 20.3; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{ClN}_2\text{O}_2$: 329.1051; Found, 329.1055.



3-Chloro-*N*-((1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3ae): The resultant residue was purified by flash silica gel column chromatography to afford **3ae** as white solid (40 mg, 61%); m.p. = 98–100 °C; ^1H NMR (CDCl_3 , 600 MHz) δ : 7.79 (t, $J = 0.8$ Hz, 1H), 7.66 (d, $J = 5.2$ Hz, 1H), 7.47–7.45 (m, 1H), 7.38–7.35 (m, 2H), 7.34–7.31 (m, 2H), 7.13 (t, $J = 3.2$ Hz, 1H), 6.90 (d, $J = 3.2$ Hz, 1H), 4.22 (dd, $J = 3.3, 13.6$ Hz, 1H), 3.26–3.24 (m, 4H), 1.47 (s, 3H); ^{13}C NMR (CDCl_3 , 150 MHz) δ : 180.2, 166.2, 142.8, 136.1, 134.8, 131.9, 131.6, 129.9, 128.6, 127.5, 124.9, 123.3, 123.1, 108.5, 47.2, 45.2, 26.3, 20.3; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{ClN}_2\text{O}_2$: 329.1051; Found, 329.1053.




2-Chloro-*N*-((1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3af): The resultant residue was purified by flash silica gel column chromatography to afford **3af** as yellow oil (42 mg, 64%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.50 (dd, $J = 0.6, 8.0$ Hz, 1H), 7.36–7.29 (m, 5H), 7.14–7.10 (m, 1H), 6.87 (d, $J = 7.8$ Hz, 1H), 4.10 (dd, $J = 7.4, 13.6$ Hz, 1H), 3.53 (dd, $J = 4.4, 13.6$ Hz, 1H), 3.22 (s, 3H), 1.49 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.8, 166.7, 143.1, 135.1, 131.7, 131.2, 130.6, 130.2, 129.9, 128.6, 127.0, 123.3, 123.1, 108.3, 47.8, 45.2, 26.3, 20.7; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{ClN}_2\text{O}_2$: 329.1051; Found, 329.1054.




4-Bromo-*N*-((1,3-dimethyl-2-oxoindolin-3-yl)methyl)benzamide (3ag): The resultant residue was purified by flash silica gel column chromatography to afford **3ag**

as colorless oil (37 mg, 50%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.69 (d, $J = 8.6$ Hz, 2H), 7.57 (d, $J = 8.6$ Hz, 2H), 7.41 (d, $J = 8.6$ Hz, 1H), 7.35–7.31(m, 2H), 7.13 (t, $J = 7.2$ Hz, 1H), 6.90 (d, $J = 7.7$ Hz, 1H), 4.24 (dd, $J = 8.4, 13.6$ Hz, 1H), 3.25 (s, 3H), 3.21 ($J = 2.6, 13.6$ Hz, 1H), 1.46 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.3, 166.5, 142.8, 133.1, 131.9, 131.8, 128.6, 126.2, 123.3, 123.0, 108.5, 47.1, 45.2, 26.3, 20.3; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{17}\text{BrN}_2\text{O}_2$: 373.0546; Found, 373.0548.




***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)-4-(trifluoromethyl)benzamide (3ah):**

The resultant residue was purified by flash silica gel column chromatography to afford **3ah** as white solid (46 mg, 63%); m.p. = 61–63 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.92 (d, $J = 8.2$ Hz, 2H), 7.70 (d, $J = 8.2$ Hz, 2H), 7.51 (d, $J = 7.0$ Hz, 1H), 7.36–7.32 (m, 2H), 7.14 (t, $J = 7.6$ Hz, 1H), 6.91 (d, $J = 7.6$ Hz, 1H), 4.26 (dd, $J = 8.4, 13.6$ Hz, 1H), 3.27–3.23 (m, 4H), 1.48 (s, 3H); ^{19}F NMR (CDCl_3 , 376 MHz) δ : 62.9; ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.2, 166.2, 142.7, 137.5, 133.4, 131.8, 128.7, 127.4, 125.6, (q, $J = 3.7$ Hz, 1C), 122.6 (q, $J = 270$ Hz, 1C), 123.2, 123.0, 108.5, 47.0, 45.2, 26.2, 20.2; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{19}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_2$: 363.1315; Found, 363.1317.




***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)nicotinamide (3ai):** The resultant residue was purified by flash silica gel column chromatography to afford **3ai** as brown oil (28 mg, 48%); ^1H NMR (CDCl_3 , 400 MHz) δ : 9.00 (s, 1H), 8.73 (d, $J = 3.9$ Hz, 1H), 8.11 (td, $J = 7.9, 1.9$ Hz, 1H), 7.43–7.32 (m, 4H), 7.6–7.12 (m, 1H), 6.92–6.90 (m, 1H), 4.24 (dd, $J = 8.2, 13.6$ Hz, 1H), 2.9, 13.6 Hz, 1H), 3.26 (s, 3H), 1.48 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.2, 165.7, 152.3, 148.3, 142.8, 134.9, 131.8, 129.9, 128.7, 123.4, 123.3, 123.1, 108.5, 47.1, 45.2, 26.3, 20.3; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_2$: 296.1394; Found, 296.1396.




***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)isonicotinamide (3aj):** The resultant


residue was purified by flash silica gel column chromatography to afford **3aj** as yellow oil (34 mg, 58%); ^1H NMR (CDCl_3 , 400 MHz) δ : 8.74 (dd, $J = 1.4, 4.5$ Hz, 2H), 7.66–7.63 (m, 3H), 7.37–7.32 (m, 2H), 7.4 (dt, $J = 0.8, 7.6$ Hz, 1H), 6.92 (d, $J = 7.8$ Hz, 1H), 4.24 (dd, $J = 8.4, 13.6$ Hz, 1H), 3.26–3.23 (m, 4H), 1.47 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.2, 165.6, 150.6, 142.7, 141.3, 131.7, 128.7, 123.3, 123.0, 120.9, 108.6, 46.9, 45.2, 26.3, 20.3; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_2$: 296.1394; Found, 296.1390.



***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)furan-2-carboxamide (3ak)**: The resultant residue was purified by flash silica gel column chromatography to afford **3ak** as yellow oil (18 mg, 31%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.46 (t, $J = 0.9$ Hz, 1H), 7.33–7.27 (m, 3H), 7.14–7.09 (m, 2H), 6.88 (d, $J = 8.2$ Hz, 1H), 6.48 (q, $J = 1.7$ Hz, 1H), 4.11 (dd, $J = 8.2, 13.6$ Hz, 1H), 3.32 (dd, $J = 3.6, 13.6$ Hz, 1H), 3.25 (s, 3H), 1.45 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.9, 158.6, 147.8, 144.1, 142.9, 131.9, 128.5, 123.1, 114.3, 112.0, 108.4, 47.4, 44.3, 26.3, 20.2; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}_3$: 285.1234; Found, 285.1237.




***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)-2-phenylacetamide (3al)** : The resultant residue was purified by flash silica gel column chromatography to afford **3al** as colorless oil (14 mg, 23%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.33–7.27 (m, 4H), 7.18 (d, $J = 7.3$ Hz, 1H), 7.08–7.05 (m, 3H), 6.80 (d, $J = 7.8$ Hz, 1H), 5.89 (s, 1H), 3.73 (dd, $J = 6.8, 13.6$ Hz, 1H), 3.47 (d, $J = 4.6$ Hz, 2H), 3.40 (dd, $J = 5.2, 13.6$ Hz, 1H), 3.10 (s, 3H), 1.30 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.5, 171.0, 142.9, 134.7, 131.6, 129.3, 129.0, 128.4, 127.4, 123.2, 123.0, 108.2, 47.9, 44.7, 43.8, 26.2, 20.2; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_2$: 309.1598; Found, 309.1595.




***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)acetamide (3am)**: The resultant residue was purified by flash silica gel column chromatography to afford **3am** as yellow oil


(23 mg, 49%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.33–7.26 (m, 2H), 7.10 (dt, $J = 0.8$, 7.6 Hz, 1H), 6.88 (d, $J = 7.8$ Hz, 1H), 6.39 (d, $J = 4.2$ Hz, 1H), 3.98 (dd, $J = 8.1$, 13.6 Hz, 1H), 3.23 (s, 3H), 3.12 (dd, $J = 3.3$, 13.6 Hz, 1H), 1.98 (s, 3H), 1.40 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.1, 170.3, 142.8, 132.0, 128.5, 123.1, 123.1, 108.3, 47.2, 44.7, 26.2, 23.3, 20.2; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{O}_2$: 233.1285; Found, 233.1288.



***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)cyclopropanecarboxamide (3an)**: The resultant residue was purified by flash silica gel column chromatography to afford **3an** as white solid (18 mg, 34%); m.p. = 160–162 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.33–7.25 (m, 2H), 7.09 (dt, $J = 0.6$, 7.6 Hz, 1H), 6.87 (d, $J = 7.8$ Hz, 1H), 6.51 (d, $J = 5.2$ Hz, 1H), 3.99 (dd, $J = 8.2$, 13.6 Hz, 1H), 3.24 (s, 3H), 3.14 (dd, $J = 3.4$, 13.6 Hz, 1H), 1.41–1.34 (m, 4H), 1.00–0.94 (m, 1H), 0.89–0.84 (m, 1H), 0.77–0.66 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.2, 173.9, 142.9, 132.1, 128.4, 123.1, 123.0, 108.3, 47.4, 44.8, 26.3, 20.1, 14.8, 7.2, 7.1; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_2$: 259.1441; Found, 259.1444.




***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)cyclohexanecarboxamide (3ao)**: The resultant residue was purified by flash silica gel column chromatography to afford **3ao** as yellow solid (23 mg, 38%); m.p. = 60–62 °C; ^1H NMR (CDCl_3 , 400 MHz) δ : 7.32–7.26 (m, 2H), 7.10 (dt, $J = 0.7$, 7.6 Hz, 1H), 6.87 (d, $J = 7.7$ Hz, 1H), 6.37 (d, $J = 4.4$ Hz, 1H), 3.95 (dd, $J = 8.0$, 13.6 Hz, 1H), 3.23 (s, 3H), 3.15 (dd, $J = 3.6$, 13.6 Hz, 1H), 2.07 (tt, $J = 3.0$, 11.3 Hz, 1H), 1.86–1.63 (m, 5H), 1.41–1.20 (m, 8H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.2, 176.2, 142.8, 132.0, 128.4, 123.1, 123.0, 108.2, 47.5, 45.5, 44.2, 29.6, 29.5, 26.2, 25.7, 25.6, 20.0; HRMS-ESI (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_2$: 309.1911; Found, 309.1913.



***N*-((1,3-Dimethyl-2-oxoindolin-3-yl)methyl)isobutyramide (3ap)**: The resultant

residue was purified by flash silica gel column chromatography to afford **3ap** as colorless oil (16 mg, 32%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.32–7.27 (m, 2H), 7.10 (t, $J = 7.6$ Hz, 1H), 6.86 (d, $J = 7.7$ Hz, 1H), 6.31 (s, 1H), 3.92 (dd, $J = 7.8, 13.6$ Hz, 1H), 3.24–3.20 (m, 4H), 2.33 (p, $J = 6.9$ Hz, 1H), 1.39 (s, 3H), 1.12 (d, $J = 6.9$ Hz, 3H), 1.03 (dd, $J = 6.9$ Hz, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 180.2, 177.1, 142.9, 132.0, 128.4, 123.2, 123.1, 108.2, 47.7, 44.3, 35.7, 26.2, 20.1, 19.5, 19.5; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_2$: 261.1598; Found, 261.1597.





tert-Butyl ((1,3-dimethyl-2-oxoindolin-3-yl)methyl)carbamate (3aq): The resultant residue was purified by flash silica gel column chromatography to afford **3aq** as colorless oil (34 mg, 59%); ^1H NMR (CDCl_3 , 400 MHz) δ : 7.31–7.25 (m, 2H), 7.08 (dt, $J = 0.8, 7.6$ Hz, 1H), 6.85 (d, $J = 7.8$ Hz, 1H), 5.10 (s, 1H), 3.64 (dd, $J = 7.8, 13.6$ Hz, 1H), 3.27–3.22 (m, 4H), 1.38 (d, $J = 7.6$ Hz, 12H); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 179.7, 155.9, 143.1, 131.9, 128.2, 123.1, 122.7, 108.0, 79.2, 48.1, 46.2, 28.2, 26.2, 19.9; HRMS-ESI (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{N}_2\text{O}_3$: 291.1703; Found, 291.1705.

10. References.



1. X. Liu, X. Ma, Y. Huang and Z. Gu, *Org. Lett.*, 2013, **15**, 4814–4817.
2. A. Pinto, Y. Jia, L. Neuville and J. Zhu, *Chem. Eur. J.*, 2007, **13**, 961–967.
3. W. Guo, Q. Wang and J. Zhu, *Angew. Chem. Int. Ed.*, 2021, **60**, 4085–4089.

11. Copies of NMR spectra



2a; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





2b; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





2c; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





2d; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





2e; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





2f; ^1H NMR (600 Hz, CDCl_3); ^{13}C NMR (150 Hz, CDCl_3)





2g; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





2h; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





2i; ^1H NMR (400 Hz, D_2O); ^{13}C NMR (100 Hz, D_2O)





2j; ^1H NMR (400 Hz, D_2O); ^{13}C NMR (100 Hz, D_2O)





2k; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





21; ^1H NMR (400 Hz, $(\text{CD}_3)_2\text{CO}$); ^{13}C NMR (100 Hz, $(\text{CD}_3)_2\text{CO}$)





2m; ^1H NMR (400 Hz, $(\text{CD}_3)_2\text{CO}$); ^{13}C NMR (100 Hz, $(\text{CD}_3)_2\text{CO}$)





2n; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





2o; ^1H NMR (400 Hz, $(\text{CD}_3)_2\text{CO}$); ^{13}C NMR (100 Hz, $(\text{CD}_3)_2\text{CO}$)





2p; ^1H NMR (400 Hz, $(\text{CD}_3)_2\text{CO}$); ^{13}C NMR (100 Hz, $(\text{CD}_3)_2\text{CO}$)





2q; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3a; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3b; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3c; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3d; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3e; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)




3f; ^1H NMR (600 Hz, CDCl_3); ^{13}C NMR (150 Hz, CDCl_3)





3g; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3); ^{19}F NMR (376 Hz, CDCl_3)









3h; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3i; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3j; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3k; ^1H NMR (600 Hz, CDCl_3); ^{13}C NMR (150 Hz, CDCl_3)




3i; ^1H NMR (600 Hz, CDCl_3); ^{13}C NMR (150 Hz, CDCl_3)





3m; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3); ^{19}F NMR (376 Hz, CDCl_3)









3n; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)




3o; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3p; ^1H NMR (600 Hz, CDCl_3); ^{13}C NMR (150 Hz, CDCl_3); ^{19}F NMR (376 Hz, CDCl_3)









3q; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3r; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3s; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3t; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3u; ^1H NMR 600 Hz, CDCl_3 ; ^{13}C NMR (150 Hz, CDCl_3)





3ab; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3ac; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3ad; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3ae; ^1H NMR (600 Hz, CDCl_3); ^{13}C NMR (150 Hz, CDCl_3)





3af; ^1H NMR (600 Hz, CDCl_3); ^{13}C NMR (150Hz, CDCl_3)




3ag; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3ah; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3); ^{19}F NMR (376 Hz, CDCl_3)









3ai; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3aj; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3ak; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3al; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3am; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)





3an; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)



3ao; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)



3ap; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)



3aq; ^1H NMR (400 Hz, CDCl_3); ^{13}C NMR (100 Hz, CDCl_3)

